EU drugs agency endorses Gilead’s remdesivir as Covid-19 therapy
Remdesivir has been approved for emergency use in the US, India and South Korea, and has received full approval in Japan
25 June 2020 - 18:52
Bengaluru — Doctors in Europe will soon be able to treat Covid-19 patients with Gilead's antiviral drug, remdesivir, after the health regulator's endorsement put it on track to become the first therapy for the disease on the continent.
The European Medicines Agency (EMA) said on Thursday its human medicines committee recommended conditionally approving the drug for adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support. ..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.